Literature DB >> 27021326

Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014.

David J Farrell1, Rodrigo E Mendes1, Mariana Castanheira1, Ronald N Jones2.   

Abstract

Fusidic acid (FA) activity was evaluated against 2,002 clinical staphylococcal isolates collected in U.S. hospitals during 2014. FA (MIC50/90, 0.12/0.12 μg/ml) inhibited 99.8% of Staphylococcus aureus isolates at ≤1 μg/ml. Only four S. aureus isolates displayed FA values of >2 μg/ml (three strains with fusC and one with an L461K substitution in fusA), and they were isolated from patients in four states. In conclusion, FA demonstrated sustained, potent activity against this recent collection of U.S. staphylococci.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27021326      PMCID： PMC4879425          DOI： 10.1128/AAC.00238-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus.

Authors:  Stan Deresinski
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

2.  Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France.

Authors:  F Laurent; A Tristan; M Croze; M Bes; H Meugnier; G Lina; F Vandenesch; J Etienne
Journal:  J Antimicrob Chemother       Date:  2008-11-01       Impact factor: 5.790

3.  In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

Authors:  Robert K Flamm; Rodrigo E Mendes; Patricia A Hogan; James E Ross; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-12-30       Impact factor: 2.803

4.  Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).

Authors:  Mariana Castanheira; Amy A Watters; Rodrigo E Mendes; David J Farrell; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

Review 5.  Fusidic acid in septicaemia and endocarditis.

Authors:  M Whitby
Journal:  Int J Antimicrob Agents       Date:  1999-08       Impact factor: 5.283

6.  In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.

Authors:  Ronald N Jones; Rodrigo E Mendes; Helio S Sader; Mariana Castanheira
Journal:  Clin Infect Dis       Date:  2011-06       Impact factor: 9.079

7.  Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use.

Authors:  Olajumoke Sule; Nicholas M Brown; Lorna J Willocks; Jane Day; Sonal Shankar; Christopher R Palmer; Nigel P Burrows
Journal:  Int J Antimicrob Agents       Date:  2007-05-01       Impact factor: 5.283

Review 8.  Fusidic acid: new opportunities with an old antibiotic.

Authors:  J D Anderson
Journal:  Can Med Assoc J       Date:  1980-04-05       Impact factor: 8.262

Review 9.  Fusidic acid resistance in Staphylococcus aureus.

Authors:  D Dobie; J Gray
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

Review 10.  Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.

Authors:  G Cornaglia; G M Rossolini
Journal:  Clin Microbiol Infect       Date:  2009-03       Impact factor: 8.067
View more
  5 in total

Review 1.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

2.  Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.

Authors:  Wafi Siala; Hector Rodriguez-Villalobos; Prabhavathi Fernandes; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.

Authors:  Mehdi Goudarzi; Bahareh Hajikhani; Sareh Kakavandi; Sana Amini; Samira Zamani; Alex van Belkum; Hossein Goudarzi; Masoud Dadashi
Journal:  Antimicrob Resist Infect Control       Date:  2021-05-01       Impact factor: 6.454

4.  Comparative Genomic Analyses Reveal Potential Factors Responsible for the ST6 Oxacillin-Resistant Staphylococcus lugdunensis Endemic in a Hospital.

Authors:  Shih-Cheng Chang; Lee-Chung Lin; Jang-Jih Lu
Journal:  Front Microbiol       Date:  2021-11-25       Impact factor: 5.640

5.  The widespread use of topical antimicrobials enriches for resistance in Staphylococcus aureus isolated from patients with atopic dermatitis.

Authors:  C P Harkins; M A McAleer; D Bennett; M McHugh; O M Fleury; K A Pettigrew; K Oravcová; J Parkhill; C M Proby; R S Dawe; J A Geoghegan; A D Irvine; M T G Holden
Journal:  Br J Dermatol       Date:  2018-07-24       Impact factor: 9.302
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.